Dextera Biosciences is developing a new category of drugs, Synthetic D-Proteins, to overcome the limitations of current drug modalities. Synthetic D-Proteins exhibit antibody-like specificity to a single therapeutic target but with the broad distribution of small molecules, all while being otherwise “invisible” to the rest of the body. The consequences are that we can deliver sustained antibody-like activity specifically to interstitial targets, enable oral delivery with complete metabolic stability, and extend therapeutic durability with no immunogenicity. We are focusing on debilitating diseases where significant unmet need remains due to the limitations of current drugs.
Company Details
- Employees
- 11
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.dexterabio.com
- Keywords
- Newton.
Dextera Biosciences Questions
Dextera Biosciences's website is http://www.dexterabio.com
Dextera Biosciences's LinkedIn profile is https://www.linkedin.com/company/dextera-biosciences
Dextera Biosciences has
11 employees.
View email and phone details for 11
employees at Dextera Biosciences.
Dextera Biosciences's industry is
Biotechnology Research
Dextera Biosciences's top competitors are
Reflexion Pharmaceuticals,
Clearview Healthcare Partners,
Rhea's Factory,
Axent Biosciences,
Bighat Biosciences,
Dextera,
Pinkdx, Inc.,
Minutia,
Adamas Pharmaceuticals, Inc.,
Bevc.
Dextera Biosciences's categories are Biotechnology Research
